Salt Forms of Semaglutide: Why the FDA Says They're Unapproved
Key Takeaways
- Semaglutide base is the form used in FDA-approved Ozempic/Wegovy — it's the only "approved" form
- Semaglutide sodium and semaglutide acetate are salt forms — the FDA considers them different chemical entities
- Salt forms have never been through FDA approval for any indication
- Some compounding pharmacies use salt forms because they're easier to source or formulate
- The FDA has actively warned against salt form compounding as legally and medically unapproved
The salt form issue is one of the most technical — and most important — topics in compounded GLP-1 safety. The chemistry matters because it affects whether your medication is legally and pharmacologically what you think it is.
What's a Salt Form?
In pharmaceutical chemistry, a "salt form" is a version of a drug that's been combined with an acid or base to change its physical properties (solubility, stability, shelf life). Semaglutide base, semaglutide sodium, and semaglutide acetate all contain the semaglutide molecule — but they're not identical products.
| Form | FDA-Approved? | Used In | Compounding Status |
|---|---|---|---|
| Semaglutide (base) | Yes | Ozempic, Wegovy, Rybelsus | Legal to compound (503A) |
| Semaglutide sodium | No | Not in any approved product | FDA considers unapproved |
| Semaglutide acetate | No | Not in any approved product | FDA considers unapproved |
Why This Matters for Patients
If your compounded semaglutide uses a salt form, two concerns arise:
1. Legal: The FDA's position is that salt forms are different drugs that have never been approved — compounding them may not have a legal basis even under 503A.
2. Pharmacological: Different salt forms can have different bioavailability — meaning the same milligram dose might deliver a different amount of active drug to your bloodstream.
What to Ask Your Provider
Ask: "Is my compounded semaglutide made from semaglutide base, or a salt form?" A provider who can't answer this question, or who doesn't know, is a concern.
Embody
GLP-1 · LeadCompounded injectable semaglutide. Established program, strong clinical support. Lead anchor provider.
Uses semaglutide base form.
MadeMed
Inj. SemaCompounded injectable semaglutide. $119/mo or $89/mo on quarterly plan.
Semaglutide base is the only form with FDA approval history. Salt forms (sodium, acetate) are legally and pharmacologically riskier. Ask your provider which form your compounded product uses. If they don't know or can't confirm base form, consider switching to a provider that can.
GLP-1 Compound Pharmacy Editorial
Independent compounding pharmacy research. 503A/503B analysis, safety verification, regulatory tracking. Not medical advice.